427PPhase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. (23rd October 2018) - Moek, K L; Fiedler, W M; von Einem, J C; Verheul, H M; Seufferlein, T; de Groot, D J; Heinemann, V; Kebenko, M; Menke-van der Houven van Oordt, C W; Ettrich, T J; Rasmussen, E; Bogner, P; et al.